R&G PharmaStudies Co., Ltd. Class A

R&G PharmaStudies Co., Ltd. Class A

SSZSE:301333
51.59
CNY
-0.73
(-1.40%)
1.25EPS
54.63P/E
6.44BMarket Cap
Mar 29Next Earn
2013 Y
2014 Y
2015 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.09
1.33
1.99
3.76
4.51
5.92
6.72
8.47
7.76
9.23
7.8
8.89
10.03
Basic EPS, GAAP
0.17
0.2
0.33
0.4
0.67
1.15
1.16
1.38
1.38
2.08
1.47
1.43
1.22
Free Cash Flow per Basic Share
0.1
0.27
0.22
0.82
1.27
1.08
0.26
1.06
1.33
2.21
1.41
0.99
- -
Dividend per Share
- -
- -
0.04
0.13
0.07
- -
- -
- -
- -
0.07
0.3
0.12
0.23
Book Value per Share
0.26
0.65
1.04
1.44
2.14
3.3
4.48
5.87
16.54
18.21
18.97
20.38
20.67
Tangible Book Value per Share
0.25
0.61
0.99
1.33
2
3.05
4.16
5.62
16.4
18.02
17.89
19.32
19.65
Basic Weighted Avg Shares
72
72
71
72
72
72
72
72
82
78
95
96
95
Sales/Revenue/Turnover
78
96
142
271
326
425
484
608
638
721
744
851
957
Operating Margin (%)
17.6
17.31
20.02
14.83
18.05
100
21.14
19.75
17.58
20.56
17.54
15.87
12.75
Depreciation Expense
2
2
3
10
13
8
22
36
35
35
36
36
- -
Net Income, GAAP
12
14
24
29
48
83
84
99
113
163
140
137
117
Effective Tax Rate (%)
13.48
16.93
17.71
11.11
10.27
13.29
11.6
11.66
11.45
10.75
10.14
10.86
7.16
Profit Margin (%)
15.3
15.16
16.68
10.63
14.81
19.42
17.31
16.31
17.79
22.53
18.85
16.09
12.17
Working Capital
15
40
68
81
128
205
279
371
1,528
1,692
1,695
1,770
1,784
LT Debt
- -
- -
- -
- -
- -
- -
4
4
6
3
8
8
13
Total Equity
19
47
75
108
162
250
337
438
1,594
1,755
1,836
1,976
2,006
Return on Invested Capital (%)
- -
39.48
38.35
39.54
47.37
56.35
33.14
25.59
11.11
9.64
7.68
7.01
6.07
Return on Capital (%)
- -
44.06
38.86
28.03
32.77
38.34
27.54
24.87
11.01
9.65
7.67
6.98
5.81
Return on Common Equity (%)
- -
44.06
38.86
32.28
37.56
42.21
29.91
26.63
11.29
9.74
7.83
7.2
6

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
35
34
37
LT Borrowings
- -
- -
- -
LT Finance Leases
7
8
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
97
97
97
Market Capitalization
6,630
4,838
6,439

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,162
2,163
2,168
Cash, Cash Equivalents & STI
1,719
1,672
1,665
Accounts Receivable, Net
138
178
177
Inventories
56
53
50
Total Current Liabilities
359
372
384
Payables & Accruals
- -
- -
- -
ST Debt
35
34
37
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
55.88%
63.26%
7.6%
Free Cash Flow
58.49%
71.87%
-29.57%
Net Income, GAAP
28.51%
11.97%
-2.37%
Sales/Revenue/Turnover
26.5%
12.21%
14.38%
Total Cash Common Dividend
- -
- -
-58.49%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
177
202
183
182
744
2025
173
207
- -
244
851
2026
218
250
246
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
0.37
0.27
0.59
1.47
2025
0.27
0.37
- -
0.43
1.43
2026
0.24
0.23
0.32
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.1
0.3
2025
- -
- -
- -
0.06
0.12
2026
0.05
0.05
0.07
- -
- -

Company Description

CEO
Jie Wu
Full Time Employees
2,645
Sector
Health technology
Industry
Biotechnology
Address
Beijing China
IPO Date
Aug 2, 2022
Business
R&G PharmaStudies Co., Ltd. is a China-based contract research organization that provides full-process, integrated clinical research and development outsourcing services for pharmaceutical, biotechnology, and medical device companies, as well as academic and research institutions globally. Founded in 2008 and headquartered in Beijing, China, the company operates across two principal business segments: Clinical Trial Technical Services and Clinical Trial Related and Laboratory Services. Its comprehensive portfolio of clinical solutions comprises clinical trial operations covering protocol development, project management, medical monitoring, regulatory registration, and pharmacovigilance; site management organization services providing dedicated clinical research coordinators, investigator site selection, patient recruitment, and trial compliance management; clinical data management and biostatistical analysis encompassing electronic data capture implementation, database design, data validation, CDISC-standard dataset conversion, SAS statistical programming, and clinical study report preparation; bioanalytical laboratory services delivering biological sample processing, pharmacokinetic and pharmacodynamic bioassays, biomarker analysis, and immunogenicity testing; clinical pharmacology consulting offering early-phase trial design, quantitative pharmacology modeling, exposure-response analysis, and translational science; and comprehensive regulatory and medical strategy consulting supported by an Innovative Drug Science and Strategy Committee assisting clients with clinical trial applications and marketing authorizations before the National Medical Products Administration, the U.S. Food and Drug Administration, the European Medicines Agency, and the Pharmaceuticals and Medical Devices Agency. The company maintains extensive operational coverage across mainland China and conducts international operations through its specialized United States subsidiary, R&G US Inc., with offices in Maryland and New Jersey focused on global trial design, regulatory strategy, and advanced biostatistical services. Controlled by ACE UNION HOLDING LIMITED, the company trades on the ChiNext market of the Shenzhen Stock Exchange under the ticker symbol 301333. In recent operational and strategic developments, R&G PharmaStudies expanded its long-standing strategic collaboration with Dassault Systèmes' Medidata, adopting the Medidata Data Experience suite—including Medidata Rave, Randomization and Trial Supply Management, and Data Surveillance solutions—to advance trial digitalization, optimize data quality oversight, and accelerate multi-regional clinical trials. Furthermore, the company instituted an employee equity incentive program to align workforce incentives with long-term growth, refined its internal corporate governance and material reporting frameworks, and broadened its overseas clinical consulting and pharmacology capabilities to support biopharmaceutical developers pursuing international clinical development.